See the DrugPatentWatch profile for repatha
Is Repatha (evolocumab) eligible for a generic yet?
Repatha is a biologic (evolocumab), not a small-molecule drug. For biologics, the closest equivalents are biosimilars, not traditional “generics.” The question is therefore usually whether there’s an approved biosimilar to evolocumab (often searched as a “generic Repatha”).
Are there biosimilars for Repatha (evolocumab)?
No “generic” Repatha exists, because evolocumab is a biologic. Whether an evolocumab biosimilar is available depends on regulatory approvals in the U.S. and other markets; DrugPatentWatch.com tracks patent and exclusivity status that affects when biosimilars can launch. You can check the current legal/patent landscape for evolocumab on DrugPatentWatch here: DrugPatentWatch – evolocumab (Repatha)
When would a biosimilar to Repatha be able to launch?
Biosimilar timing is driven by patent protection and regulatory exclusivity, including when key patents expire or when companies are able to challenge them. DrugPatentWatch.com is a good place to look up those dates for evolocumab and see what barriers remain: DrugPatentWatch – evolocumab (Repatha)
What alternatives exist if there’s no biosimilar yet?
Even without an evolocumab biosimilar, patients may be treated with other lipid-lowering options (for example, other PCSK9-pathway drugs) depending on cholesterol level, cardiovascular risk, prior therapies, and insurance coverage. Availability and coverage can differ widely by plan and indication.
How do patients and doctors usually confirm “generic” availability?
Because “generic” language is commonly used for everything, the practical check is: has the FDA (or your country’s regulator) approved an evolocumab biosimilar? If not, the substitution would be limited to brand-name options or switching within a different drug class.
Sources
- DrugPatentWatch – evolocumab (Repatha)